等待开盘 11-18 09:30:00 美东时间
-1.510
-1.81%
Aardvark Therapeutics reported that the FDA lifted the clinical hold on ARD-101 for treating hyperphagia in Prader-Willi Syndrome (PWS). The company plans to resume PWS clinical activities in 2027 following a meeting with the FDA scheduled for the first quarter of 2027. Exploratory data from terminated trials showed ARD-101 may reduce HQ-CT scores more than placebo, with a generally well-tolerated safety profile. The company had $60.3 million in ...
11-13 13:00
今日重点评级关注:BTIG:维持Rapport Therapeutics"买入"评级,目标价从75美元升至89美元;摩根士丹利:维持希捷科技"超配"评级,目标价从1187美元升至1200美元
10-21 12:30
Guggenheim analyst Yatin Suneja reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
10-20 20:52
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – Se...
10-01 04:16
Kodiak暴升178%!wAMD三期临床试验大获成功;AMC升近12%,39.7亿美元债务再融资;黑莓升逾7%,Q2营收超预期,QNX业务表现强劲>>
09-29 17:03
Grail暴升57%,首个多癌早筛PMA获专家组支持;Moderna飙升29%,市场关注黑色素瘤研究三期结果;Credo升近20%,ECOC展示1.6T AI光互联新品>>
09-28 17:49
今日重点评级关注:Citizens:上调Quince Therapeutics评级至"跑赢大市",目标价77美元;康托·菲茨杰拉德:维持塞德斯医疗"超配"评级,目标价从61美元升至72美元
09-23 15:30
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-22 21:50
Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday. The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1...
09-22 21:28
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
09-22 20:40